U.S. markets closed

Landos Biopharma, Inc. (LABP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.51+0.24 (+2.13%)
At close: 4:00PM EDT
Sign in to post a message.
  • D
    The Company 'Tried'. Thank you for your efforts, but it seems that you better change directions (maybe try another compound/drug). unfortunately, the stocks heading Lower (imo).
  • M
    Today was a great buy day for LABP
  • j
    Landos is still under the radar
  • Y
    Yahoo Finance Insights
    LABP is up 17.43% to 15.83
  • j
    $60,000,000 went into this @ $16...... The cheapest insider buy is @ $11.15.... No brainer since it's already late stage phase III
  • S
    if it goes to 13 bucks again i am loading the boat
  • S
    Sheldon J.
    Wow this is going to the moon
  • S
    On January 4, the company announced slightly murky data from its first-in-patients 12-week Phase II proof-of-concept trial of BT-11 for mild to moderate ulcerative colitis. The drug is a novel, orally administered, gut-restricted LANCL2 modulator. The trial enrolled 198 UC patients at 53 sites in the U.S., Europe and Russia. There were two dosing cohorts, 500 mg and 1,000 mg compared to placebo. Clinical remission was evaluated over a 12-week induction period, which was defined by the 3-component modified Mayo Score, using a rectal bleeding subscore of 0, a stool frequency subscore of 0 or 1, and an endoscopic subscore of 0 or 1.

    There was a positive trend in absolute clinical remission rates for both doses: 31.8% for 1,000 mg; 30.3% for 500 mg; 22.7% for placebo. The placebo-adjusted clinical remission rates were 9.1% for the 1000 mg dose and 7.6% for the 500 mg dose.

    Essentially, the trial missed all its primary endpoints in IBD, although there were some positive signs, after adjusting for placebo values, that it was similar to standard of care.
    The company plans to list on the Nasdaq under the LABP ticker symbols. It will remain to be seen if the Phase II trial’s data, which had disappointing p-values, forcing it to miss the primary endpoints, will discourage investors, or if the promise of the company’s overall approach will stimulate intrigue and interest.
  • S
    Two Insiders purchased $20M each yesterday for $14.10.

    Perhaps they know something we don't know that should instill more confidence in us???
  • B
    stocktwits has a much more ative informative board
  • P
    I’m in. This board is lifeless
  • F
    $SANA conversation
    Wow, a $6.4B completely preclinical company, burning cash at $172M/year, clearly needing to raise (a lot) more cash to survive till any of the candidate finish trial III. Interestingly, a definitely more solid company like $LABP debuting on the same day and instantly dropped 25% from IPO price. I guess gene editing is all the rage.
  • F
    Insider very confident on $LABP: board of director Poukalov Konstantin just filed form 4 with SEC indicate that his funds bought 240K shares of LABP in open market from $11 to $14+. Saw this news in my Fidelity account, dated today 2/9 at 7:56 pm. I think LABP will continue to ascend.
  • F
    Finally people realized that LABP is undervalued compared to other recent Biopharma IPOs! Read my previous post about LABP specifically for why you should buy and hold LABP at least for a while. GLTAL!
  • s
    Initiated by SVB Leerink Outperform USD 20
    Initiated by Raymond James Financial Outperform USD 33
    Initiated by Jefferies Buy USD 32
    Initiated by JPMorgan Chase Neutral USD 17
  • S
    Disastrous IPO :-((
    from 16 $ to 10 $ in just 2 days
    completely mispriced offering
  • o
    tumbled out of the gate.
  • S
    Landis has been around for a few years and working on some interesting biotech solutions. Definitely something to look into once the initial IPO spike dies down.
  • N
    Guys QST has very great potential. Financials are great and stock is undervalued you should check once.
  • M
    What is the debt and cash position at LABP?